Thiotepa for Injection, USP Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Thiotepa for Injection, USP, in 15 mg per vial in a single-dose vial and 100 mg per vial in a single-dose vial.

Meitheal will offer Thiotepa for Injection, USP, in a pack of 1 vial for both presentations.


Thiotepa for Injection is an alkylating drug indicated:

  • For treatment of adenocarcinoma of the breast or ovary.
  • For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
  • For treatment of superficial papillary carcinoma of the urinary bladder.

For full prescribing information, please click on the following link.

Learn more about Thiotepa for Injection, USP

This Website Uses Cookies

This website uses cookies to help us give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can read more about our use of cookies in our Privacy Policy.

Accept cookies Reject cookies